Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States
Tempus AI, Inc. - Class A (TEM)
Company Research
Source: Business Wire
The collaboration follows FDA 510(k) clearance for eyonis® LCS and aims to integrate high-performance lung cancer screening detection and diagnosis device into the clinical workflow through the Tempus Pixel platform. SOPHIA ANTIPOLIS, France & CHICAGO--(BUSINESS WIRE)--Regulatory News:Median Technologies (FR0011049824, ALMDT, “Median” or the “Company”), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a provider of AI-enhanced and central imaging services for oncology drug developers, today announced its non-exclusive distribution agreement with Tempus AI, Inc. (NASDAQ: TEM) a technology company leading the adoption of AI to advance precision medicine.Under the agreement, Tempus AI will distribute eyonis® LCS to U.S. imaging providers through the Tempus Pixel platform and support implementation, customer onboarding, and workflow integration. Tempus Pixel1 is an FDA-cleared, CE-marked AI-enabled
Show less
Read more
Impact Snapshot
Event Time:
TEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEM alerts
High impacting Tempus AI, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
TEM
News
- Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel PlatformBusiness Wire
- Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24Business Wire
- Tempus AI, Inc. (TEM): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Ambry’s Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New GenesBusiness Wire
- Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield [Yahoo! Finance]Yahoo! Finance
TEM
Earnings
- 11/4/25 - Beat
TEM
Sec Filings
- 2/10/26 - Form SCHEDULE
- 2/4/26 - Form 4
- 1/30/26 - Form 4
- TEM's page on the SEC website